

## GULF COAST TotalCare

# FY25 2<sup>ND</sup> Quarter Medical Management Meeting February 2025



# Routine Postpartum Care and

## Postpartum Quality Measure



- Measures the percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. Includes members who delivered in any setting.
- For these members, the measure assesses the percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery.
- Includes multiple births. Members who had two separate deliveries
   (different dates of service) between October 8 of the year prior to the
   measurement year and October 7 of the measurement year count twice.
   Members who had multiple live births during one pregnancy count once.

#### **Postpartum Quality Measure**



- Exclusions include hospice, death and non live births
- Types of encounters that qualify include a routine post-partum visit, cervical cytology, a bundled service where the date of the postpartum care is identified.
- Acute inpatient visits do NOT count.

## Components of a Postpartum Visit Needed



- Pelvic exam
- Evaluation of weight, BP, breasts and abdomen (notation that the mom is breastfeeding is acceptable for breast exam)
- Notation of postpartum care
- Perineal or cesarean incision/wound check

# Components of a Postpartum Visit Needed



- Screening for depression, anxiety, tobacco use, substance abuse disorder, or pre-existing mental health disorders\
- Glucose screening for members that had gestational diabetes
- Documentation of infant care or breastfeeding, resumption of intercourse, birth spacing, family planning, sleep/fatigue, resumption of physical activity and attainment of a healthy weight

### **Optimizing Postpartum Care**



- Postpartum care is an ongoing process
- Timing for the postpartum visits should be individualized
- An initial assessment should be within the first 3 weeks to address acute postpartum issues
- A comprehensive well-woman visit should occur no later than 12 weeks after birth, and should include full assessment of physical, social and psychological well-being

# Postpartum Mood Postpartum Blues



- Develops in up to 40 % women within one week of delivery
- A transient condition develops within 2-3 days after delivery, resolves within two weeks of onset.
- Mild depressive symptoms: sadness, crying, insomnia, anxiety and mood lability
- Self limited condition: ensure adequate time to sleep and rest
- Watch for signs for postpartum depression

#### **Postpartum Depression**



- About 10 % of women suffer from postpartum depression
- All postpartum women should be screened for postpartum depression

#### Evaluation:

- History: mood swings, concentration, crying, anxiety, appetite, etc.
- Screening tools: PHQ-2, PHQ-9, Edinburgh Postnatal Depression Scale
- Screening at 6 weeks and 3 months postpartum visits

#### Management:

- Mild to moderate depression with no prior history: psychotherapy
- Mild to moderate depression with prior history: initiate pharmacotherapy.
- SSRI as initial treatment option for breast feeding women (Paroxetine or sertraline)

### **Postpartum Care: GDM**



- GDM increase maternal risk of type 2 diabetes later in life.
- Breastfeeding improves maternal glucose metabolism
- Screening for overt diabetes:
  - Check glucose 24-72 hour after delivery
  - Two-hour 75 gm oral GTT 4-12 weeks postpartum
  - A1c at one year after delivery
  - Ongoing lifestyle changes for risk reduction

## Online Viewing Code



# 22025

# Postpartum Care: Gestational Hypertensive Disorder



- Increases risk of developing chronic hypertension later in life, as well as Cardiovascular disease, hyperlipidemia and chronic kidney disease.
- Blood pressure normalization after delivery:
  - Within the first week after delivery, two weeks for preeclamptic pregnancy.
  - Transient hypertension of pregnancy: blood pressure returns to normal by 12-week postpartum
- Early postpartum visit for blood pressure check:
  - within 3-10 days after delivery
- Choice of antihypertensive postpartum is same as during pregnancy

### **Postpartum Contraception**



- Optimal interpregnancy interval is 18-59 months.
- Average ovulation in nonlactating postpartum women starts from 45-94 days with earliest at 25 days.
- More than 50% couples will resume sexual activity by 6-week postpartum.
- Important to address contraception plan at 3-week visit!

## **Postpartum Contraception**



- Can be initiated immediately postpartum:
  - Female/male sterilization
  - Progastrin-only implants
  - Intrauterine devices
  - The Progestin injection
  - Progestin-only pills

#### **Postpartum Contraception**



- Special considerations
  - Combined hormonal contraception:
    - Evidence does not support significant effect of hormonal contraception on breastfeeding outcomes
    - Delay for at least 30 days to decrease VTE risk, six weeks if women with additional VTE risk factors
  - Women with depression
    - Both combined hormonal contraception and progestin-only methods can be used
  - BMI>30: IUDs and implants are least associated with weight gain



- Parents should be given instructions on feeding the infant, stooling and urination expectations, umbilical cord care, skin care, genital care and signs of illness prior to discharge
- Car seats should be inspected to ensure the safety of the infant.
   Proper car seat size and use is critical.
- Follow-up appointments should be facilitated prior to discharge
- Most infants who are healthy, breastfeeding or have left the hospital after 48 hours can be seen in 3-5 days
- If there are any health concerns or the infant left the hospital less than 48 hours, the infant should be seen earlier.

#### **Areas to Address**



- General health of the infant
- Quality of the mother-infant interaction
- Infant behavior
- Feeding
- Stooling and urination
- Review outstanding lab tests/hearing, vision, vaccinations and the newborn screen if available
- Recheck any labs or tests that the infant did not pass
- Parental well being



- Provide parents with resources for breastfeeding, WIC, and address any social determinants of health
- A good maternal pregnancy and birth history should be obtained
- Discuss infant safety with parents

|  | INFANCY               |                      |                    |         |      |      |      |      |        |
|--|-----------------------|----------------------|--------------------|---------|------|------|------|------|--------|
| AGE <sup>1</sup>                                       | Prenatal <sup>2</sup> | Newborn <sup>1</sup> | 3-5 d <sup>s</sup> | By 1 mo | 2 mo | 4 mo | 6 mo | 9 mo | 12 mo  |
| HISTORY<br>Initial/Interval                            | •                     | •                    | •                  | •       | •    | •    | •    | •    | •      |
| MEASUREMENTS   |                       |                      |                    |         |      |      |      |      |        |
| Length/Height and Weight                               |                       | •                    | •                  | •       | •    | •    | •    | •    | •      |
| Head Circumference                                     |                       | •                    | •                  | •       | •    | •    | •    | •    | •      |
| Weight for Length                                      |                       | •                    | •                  | •       | •    | •    | •    | •    | •      |
| Body Mass Index <sup>1</sup>                           |                       |                      |                    |         |      |      |      |      |        |
| Blood Pressure <sup>s</sup>                            |                       | *                    | *                  | *       | *    | *    | *    | *    | *      |
| SENSORY SCREENING                                      |                       |                      |                    |         |      |      |      |      |        |
| Wision?  |                       | *                    | *                  | *       | *    | *    | *    | *    | *      |
| Hearing  |                       | • t                  | •°-                |         | -    | *    | *    | *    | *      |
| DEVELOPMENTAL/SOCIAL/BEHAVIORAL/MENTAL HEALTH          |                       |                      |                    |         |      |      |      |      |        |
| Maternal Depression Screening <sup>11</sup>            |                       |                      |                    | •       | •    | •    | •    |      |        |
| Developmental Screening <sup>12</sup>                  |                       |                      |                    |         |      |      |      | •    |        |
| Autism Spectrum Disorder Screening <sup>11</sup>       |                       |                      |                    |         |      |      |      |      |        |
| Developmental Surveillance                             |                       | •                    | •                  | •       | •    | •    | •    |      | •      |
| Behavioral/Social/Emotional Screening <sup>14</sup>    |                       | •                    | •                  | •       | •    | •    | •    | •    | •      |
| Tobacco, Alcohol, or Drug Use Assessment <sup>11</sup> |                       |                      |                    |         |      |      |      |      |        |
| Depression and Suicide Risk Screening <sup>14</sup>    |                       |                      |                    |         |      |      |      |      |        |
| PHYSICAL EXAMINATION®                                  |                       | •                    | •                  | •       | •    | •    | •    | •    | •      |
| PROCEDURES18   |                       |                      |                    |         |      |      |      |      |        |
| Newborn Blood  |                       | ₱ <sup>19</sup>      | ● <sup>20</sup> -  |         | -    |      |      |      |        |
| Newborn Bilirubin <sup>21</sup>                        |                       | •                    |                    |         |      |      |      |      |        |
| Critical Congenital Heart Defect <sup>20</sup>         |                       | •                    |                    |         |      |      |      |      |        |
| Immunization <sup>21</sup>                             |                       | •                    | •                  | •       | •    | •    | •    | •    | •      |
| Anemia <sup>24</sup>                                   |                       |                      |                    |         |      | *    |      |      | •      |
| Lead <sup>21</sup>                                     |                       |                      |                    |         |      |      | *    | *    | • or * |
| Tuberculosis <sup>27</sup>                             |                       |                      |                    | *       |      |      | *    |      | *      |
| Dyslipidemia <sup>28</sup>                             |                       |                      |                    |         |      |      |      |      |        |
| Sexually Transmitted Infections <sup>24</sup>          |                       |                      |                    |         |      |      |      |      |        |
| HV <sup>cc</sup>                                       |                       |                      |                    |         |      |      |      |      |        |
| Hepatitis B Virus Infection <sup>(1)</sup>             |                       | *                    |                    |         |      |      |      |      |        |
| Hepatitis C Virus Infection™                           |                       |                      |                    |         |      |      |      |      |        |
| Sudden Cardiac Arrest/Death™                           |                       |                      |                    |         |      |      |      |      |        |
| Cervical Dysplasia <sup>™</sup>                        |                       |                      |                    |         |      |      |      |      |        |
| ORAL HEALTH**  |                       |                      |                    |         |      |      | ● ≥  | ●36  | *      |
| Fluoride Varnish <sup>10</sup>                         |                       |                      |                    |         |      |      | 4    |      |        |
| Fluoride Supplementation <sup>18</sup>                 |                       |                      |                    |         |      |      | *    | *    | *      |
| ANTICIPATORY GUIDANCE                                  | •                     | •                    | •                  | •       | •    | •    | •    | •    | •      |

#### Questions



#### Please reach out with any questions:

 Haleigh Tapscott, Executive Director <u>hptapscott@uabmc.edu</u>

 Ann Payne-Johnson M.D., M.S., Medical Director apjohnson@health.southalabama.edu

 Genevieve Mantell BSN, RN, Quality Director gmantell@uabmc.edu

